News · 26 weeks490%
2026-03-012026-08-23
Mix2790d
- SEC Filings9(33%)
- Other7(26%)
- Insider7(26%)
- Offering3(11%)
- Analyst1(4%)
Latest news
25 items- PRAEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the Company's regulatory leadership. Dr. Lee and Clintrex current
- SECSEC Form SCHEDULE 13G filed by AEON Biopharma Inc.SCHEDULE 13G - AEON Biopharma, Inc. (0001837607) (Subject)
- INSIDERLarge owner Lynch Timothy P bought $243,455 worth of shares (1,150,000 units at $0.21), increasing direct ownership by 21% to 6,500,000 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERNew insider Lynch Timothy P claimed ownership of 5,350,000 shares (SEC Form 3)3 - AEON Biopharma, Inc. (0001837607) (Issuer)
- PRAEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation - Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX® - FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development ALISO VIEJO, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- AEON Biop
- SECSEC Form 10-Q filed by AEON Biopharma Inc.10-Q - AEON Biopharma, Inc. (0001837607) (Filer)
- SECAEON Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - Upfront proceeds from financing provide cash runway into the first quarter of 2027 ALISO VIEJO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. "The second quarter marked co
- SECAEON Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Regains Compliance with NYSE American Continued Listing StandardsALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice from NYSE American LLC ("NYSE American") confirming that AEON has regained compliance with NYSE American’s continued listing standards relating to stockholders’ equity. On August 3, 2026, the Company received a letter from NYSE Regulation confirming that the Company had resolved the previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE Ame
- ANALYSTLake Street initiated coverage on AEON Biopharma with a new price targetLake Street initiated coverage of AEON Biopharma with a rating of Buy and set a new price target of $1.00
- SECAEON Biopharma Inc. filed SEC Form 8-K: Other Events8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form SCHEDULE 13G filed by AEON Biopharma Inc.SCHEDULE 13G - AEON Biopharma, Inc. (0001837607) (Subject)
- SECAEON Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form 424B4 filed by AEON Biopharma Inc.424B4 - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future FundingIRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering. The offering consists of 42,688,606 shares of common stock of the Company
- SECSEC Form EFFECT filed by AEON Biopharma Inc.EFFECT - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form S-1MEF filed by AEON Biopharma Inc.S-1MEF - AEON Biopharma, Inc. (0001837607) (Filer)
- SECAmendment: SEC Form S-1/A filed by AEON Biopharma Inc.S-1/A - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form S-1 filed by AEON Biopharma Inc.S-1 - AEON Biopharma, Inc. (0001837607) (Filer)
- INSIDERDirector Thunen Shelley B was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERDirector Palmisano Robert J was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERDirector Forth Marc was granted 222,684 shares, increasing direct ownership by 30% to 973,231 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERDirector Fischer Jost was granted 222,684 shares, increasing direct ownership by 83% to 489,469 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERDirector Carter Eric G was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
AEON FAQ
5 questionsWhere does AEON stock trade?
AEON Biopharma Inc. (AEON) is listed on AMEX.What sector and industry is AEON in?
AEON Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AEON?
AEON Biopharma Inc. has had 2 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $100.00 price target on 2026-07-30.What companies are similar to AEON?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AEON side-by-side with any of them on Quantisnow.How can I track AEON on Quantisnow?
Quantisnow aggregates AEON Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AEON to receive live email and push alerts on every new disclosure.